21:36:33 EST Fri 15 Jan 2021
Enter Symbol
or Name

Login ID:
Trillium Therapeutics Inc (2)
Symbol TRIL
Shares Issued 98,378,265
Close 2020-11-12 C$ 18.47
Recent Sedar Documents

Trillium Therapeutics appoints Pucci to board

2020-11-12 16:20 ET - News Release

Mr. James Parsons reports


Trillium Therapeutics Inc. has appointed pharmaceutical industry leader Paolo Pucci to its board of directors, effective immediately. Mr. Pucci has significant expertise in oncology drug development and decades of leadership experience across large and small organizations over his 30-year career.

"We are delighted to welcome Mr. Pucci to the board of directors," said Robert L. Kirkman, MD, chair of Trillium Therapeutics. "His broad executive and commercial expertise, specifically in the field of oncology, will be invaluable as Trillium prepares for later-stage clinical development."

Most recently, Mr. Pucci served as chief executive officer of the targeted therapeutics oncology company, ArQule, until it was acquired by Merck for $2.7-billion in January, 2020. Prior to ArQule, Mr. Pucci served in a number of leadership positions at Bayer AG from 2001 to 2008, including president of the oncology and global specialty medicine business units ,and was a member of the Bayer pharmaceuticals global management committee. Mr. Pucci also held multiple roles at Eli Lily and Company from 1991 to 2001.

Mr. Pucci received his MS in economics and accounting from Universita degli Studi di Napoli Federico II and an MBA in marketing and finance from the University of Chicago. He currently serves as a board member of West Pharmaceuticals Services Inc., Merus NV and Replimune Inc., and had previous board roles at NewLink Genetics Inc., Dyax Inc. and Algeta ASA.

"I look forward to contributing my knowledge in oncology drug development and commercialization over the coming years," said Mr. Pucci. "There has never been a more exciting time to be developing novel oncology agents, and Trillium is well positioned in the field."

About Trillium Therapeutics Inc.

Trillium is an immuno-oncology company, developing innovative therapies for the treatment of cancer. The company's two clinical programs, TTI-621 and TTI-622, target CD47, a do-not-eat-me signal that cancer cells frequently use to evade the immune system.

© 2021 Canjex Publishing Ltd. All rights reserved.